JALSG AML/MDS/CMML Clinical Observational Study (JALSG-CS)-17

Not Applicable

• Conditions: AML(acute myeloid leukemia and related neoplasms),MDS(myelodysplastic syndromes),CMML(chronic myelomonocytic leukemia)

• Registration Number: JPRN-UMIN000027961
• Lead Sponsor: Japan Adult Leukemia Study Group (JALSG)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-06-29
• Last Update Posted: 17 October 2023
• Study Completion: 2027-08-31

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 6542

Inclusion Criteria

Not provided

Exclusion Criteria

(1)With a history of chemotherapy or hematopoietic stem cell transplantation in AML, MDS or CMML; however, treatment-related AML, MDS and CMML which developed after the following therapies are included: therapy for preceding blood abnormalities (such as immunosuppressive therapy for aplastic anemia), chemotherapy for malignancy of other tissues, radiation therapy (such as radiation therapy for preceding breast cancer, chemotherapy for preceding malignant lymphoma). (2)In case of progress from MDS or CMML to AML, re-registration is not required if it is registered with preceding MDS or CMML. MDS and CMML which had already been diagnosed outside the JALSG participating institutions are excluded. The case which developed to AML after having been diagnosed as MDS by other than those institutions and transferred to the own institution is registered as AML (with preceding blood disease). (Even if the history of abnormality of blood count is long, newly diagnosed MDS and CMML in the own institution are not excluded.)

Study & Design

• Study Type: Observational
• Study Design: Not specified